

CITATION REPORT

List of articles citing

Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

DOI: 10.1038/clpt.1991.77

Clinical Pharmacology and Therapeutics, 1991, 49, 609-17.

Source: <https://exaly.com/paper-pdf/22493572/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism. 1991 , 32, 136-7		73
104	Pharmacogenetics: Part I. 1992 , 26, 121-6		10
103	P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. 1992 , 23, 132-46		130
102	Inhibitors of imipramine metabolism by human liver microsomes. 1992 , 34, 256-61		126
101	Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. 1992 , 43, 2065-71		29
100	Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. 1992 , 44, 2089-98		180
99	Stereoselective pharmacokinetics of doxepin isomers. 1992 , 42, 539-44		25
98	Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. 1992 , 43, 405-11		42
97	Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. 1993 , 615, 265-72		11
96	Dextromethorphan O-demethylation polymorphism in Jordanians. 1993 , 45, 271-3		8
95	Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. 1993 , 44, 349-55		174
94	Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. 1993 , 23, 1289-98		22
93	Pharmacogenetics of Agents Acting on the Central Nervous System. 1993 , 6, 2-16		2
92	Genetic differences in drug disposition. 1994 , 34, 881-97		35
91	Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. 1994 , 31, 177-86		56
90	META. 1. A program for the evaluation of metabolic transformation of chemicals. 1994 , 34, 1320-5		129
89	Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. 1994 , 48, 1891-8		18

88	The role of S-mephenytoin 4Hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. 1994 , 37, 237-42	33
87	High-performance liquid chromatographic method for the analysis of imipramine metabolism in vitro by liver and brain microsomes. 1995 , 673, 251-8	21
86	Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2. 1995 , 39, 421-31	74
85	Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. 1995 , 39, 433-9	39
84	Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. 1995 , 36, 125-8	9
83	Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. 1995 , 29 Suppl 1, 10-8; discussion 18-9	104
82	"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. 1995 , 56, 2285-98	122
81	Paroxetine shifts imipramine metabolism. 1996 , 59, 189-96	45
80	Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites. 1996 , 51, 15-20	15
79	Imipramine: a model drug for P450 research. 1996 , 272, 177-86	5
78	In vitro metabolism of imipramine by brain microsomes: effects of inhibitors and exogenous cytochrome P450 reductase. 1996 , 738, 24-31	16
77	Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations. 1996 , 678, 93-103	4
76	Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18* catalyzing imipramine N-demethylation. 1996 , 271, 28176-80	40
75	Isozyme selective alterations of the expression of cytochrome P450 during regeneration of male rat liver following partial hepatectomy. 1997 , 27, 923-31	12
74	Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. 1997 , 27, 33-47	22
73	Evidence for CYP2D1-mediated primary and secondary O-dealkylation of ethylmorphine and codeine in rat liver microsomes. 1997 , 53, 603-9	7
72	Regulation of CYP3A9 gene expression by estrogen and catalytic studies using cytochrome P450 3A9 expressed in Escherichia coli. 1997 , 344, 365-72	68
71	Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia. 1997 , 16, 291-5	5

70	Metabolism of carteolol by cDNA-expressed human cytochrome P450. 1997 , 52, 479-85	23
69	Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 61, 319-24	6.1 23
68	Human cytochrome P450s: selectivity and measurement in vivo. 1998 , 28, 1095-128	95
67	Metabolism of xenobiotics in the central nervous system: implications and challenges. 1998 , 56, 547-51	38
66	Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. 1998 , 28, 493-506	20
65	Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. 1999 , 43, 549-56	3
64	Polymorphic cytochromes P450 and drugs used in psychiatry. 1999 , 19, 325-54	35
63	Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. 1999 , 73, 147-51	11
62	The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. 1999 , 9, 337-44	13
61	Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. 1999 , 9, 483-91	39
60	Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. 2000 , 10, 591-603	57
59	Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants. 2000 , 131, 287-95	33
58	Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. 2000 , 56, 231-40	31
57	Regional and cellular distribution of CYP2D subfamily members in rat brain. 2000 , 30, 547-64	70
56	Effect of venlafaxine on imipramine metabolism. 2000 , 96, 235-43	33
55	Pharmacological and toxicological significance of brain cytochromes P450. 2001 , 3, 321-8	
54	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. 2001 , 104, 173-92	285
53	Interaction between fluvoxamine and cotinine or caffeine. 2002 , 45, 32-5	11

52	Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?. 2002 , 40, 1633-56	64
51	The genetic basis of variability in drug responses. 2002 , 1, 37-44	186
50	Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. 2003 , 25, 578-82	80
49	Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. 2003 , 33 Suppl 2, 17-22	154
48	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. 2003 , 138, 1465-74	40
47	Clinical pharmacokinetics of drugs used to treat urge incontinence. 2003 , 42, 1243-85	91
46	Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. 2003 , 27, 65-73	72
45	Pharmacogenomics of Bioavailability and Elimination. 2003 , 363-380	
44	. 2003 ,	18
43	Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. 2004 , 36, 243-77	102
42	Neurobiological differences on populational level. 2004 , 28, 909-12	
41	Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. 2005 , 205, 237-46	33
40	The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. 2005 , 1, 203-17	32
39	Drug bioactivation, covalent binding to target proteins and toxicity relevance. 2005 , 37, 41-213	228
38	Genetic basis of toxic reactions to drugs and chemicals. 2006 , 162, 16-28	66
37	Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. 2006 , 34, 1516-22	37
36	Pharmacogenetics: part I: Perspective. 1992. 2007 , 41, 2042-7	
35	Relevant issues in the monitoring and the toxicology of antidepressants. 2008 , 45, 25-89	66

34	Handbook of Drug Metabolism, Second Edition. 2008 ,	
33	Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. 2008 , 31, 348-51	34
32	Nortriptyline Cardiac Toxicity Resulting from a Probable Interaction with Telithromycin. 2009 , 44, 397-400	0
31	Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. 2009 , 16, 2661-805	59
30	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. 2009 , 16, 4066-218	86
29	O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. 2009 , 65, 795-801	15
28	Polymorphism of human cytochrome P450 enzymes and its clinical impact. 2009 , 41, 89-295	579
27	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. 2009 , 48, 761-804	256
26	Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. 2009 , 19, 289-99	20
25	Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. 2000 , 52, 1473-81	11
24	Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. 2002 , 54, 1545-52	21
23	The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. 2001 , 53, 449-61	8
22	The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism. 2010 , 6, 1083-94	15
21	Safe and effective medicines for all: is personalized medicine the answer?. 2010 , 3, 627-37	0
20	Utility of Genetically Modified Animal Models for Drug Metabolism and Drug Transporters. 2012 , 1	
19	Challenges in pharmacogenetics. 2013 , 69 Suppl 1, 17-23	11
18	Drug-drug interactions in pharmacologic management of gastroparesis. 2015 , 27, 1528-41	16
17	Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications. 2015 , 47, 291-319	10

16	Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. 2015 , 30, 147-63	3
15	Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery. 2016 , 30, 301-10	10
14	The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat. 2020 , 72, 1271-1287	4
13	Role of genetic polymorphism in psychopharmacology--an update. 1993 , 10, 199-211	15
12	The emerging role of cytochrome P450 3A in psychopharmacology. 1995 , 15, 387-98	122
11	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. 1996 , 16, 273-85	61
10	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. 1996 , 16, 345-55	59
9	In Vivo and In Vitro Recombinant DNA Technology as a Powerful Tool in Drug Development. 1999 , 321-362	3
8	Death of Two Subjects Due to Imipramine and Desipramine Metabolite Accumulation During Chronic Therapy: A Review of the Literature and Possible Mechanisms. 1997 , 42, 14124J	2
7	Time of Administration of Acute or Chronic Doses of Imipramine Affects its Antidepressant Action in Rats. 2018 , 16, 5	5
6	Pharmacogenetics of antidepressants (from history to the present). 2021 , 713-729	0
5	Monoamine Oxidase Inhibitors and Tricyclic Antidepressants. 2004 , 149-173	
4	Genetischer Polymorphismus des Metabolismus von Neuroleptika: klinische Relevanz?. 1993 , 99-110	1
3	Strategies for Verifying the Involvement of Specific Cytochrome P450 Enzymes in Xenobiotic Metabolism. 1994 , 187-194	
2	Clinical Pharmacogenomics of Human CYP2D6. 2016 , 415-482	
1	Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping. <i>Journal of Psychiatry and Neuroscience</i> , 1994 , 19, 30-44	4.5 14